Despite poor growth, the company's P/S ratio exceeds industry peers, raising concerns. Investors hoping for a business turnaround may face disappointment if the P/S aligns with negative growth rates. Without significant medium-term improvements, the share price may seem overvalued.
Poor financial performance has triggered investor sell-offs. However, returns of 0.8% annually over five years and 6.4% over the past year suggest a potential opportunity if the stock's downfall is more due to market sentiment than business condition decline.
Chongqing Lummy Pharmaceuticalに関するコメント
まだコメントはありません